glp-1 agonist structure Receptor Agonists GLP-1 receptor agonist-1 | CAS#:2230197-64-3
Description
Summary Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.
Does GLP-1 cause back pain
This systematic review and meta-analysis evaluated the efficacy and safety of traditional GLP-1 RAs, DPP-4is, and SGLT-2is compared with insulin
Recently, multiple case reports and studies indicating safety risks for these medications and their use in patients planning to undergo general anesthesia have been published, as retained gastric contents can lead to intraoperative aspiration
The American Society of Anesthesiologists (ASA) recommends withholding these drugs before surgery, but definitive guidelines remain unclear
